INTRODUCTION
cancer, Breast cancer, death
CANCER, BREAST CANCER, BREAST CANCER
Breast cancer was the leading cause of cancer among women in 2020, both globally and in Japan.Evidence has suggested that Japanese patients may have better survival outcomes following treatment than American patients with breast cancer.Pembrolizumab, a humanized anti‐programmed cell death protein 1 (PD‐1) antibody, has demonstrated efficacy in patients with TNBC.Among the 847 patients enrolled in KEYNOTE‐355 worldwide, 87 patients were from Japan. Given the potential for differences in response to treatment among Japanese patients, it is important to assess outcomes in this setting. Here, we report results for the subset of patients in KEYNOTE‐355 enrolled in Japan.